 |
Prospector
Profile
07.1188
|
| |
| Achillion Pharmaceuticals, Inc. |
NAICS |
541710 |
| 300 George Street
New Haven, CT 06511 |
Description |
Biotechnology |
| (203) 624-7000 |
Employees |
66 |
| http://www.achillion.com/ |
Revenue |
(mil) |
0.0030 |
| |
Income |
(mil) |
-28.2490 |
| |
Assets |
(mil) |
67.1460 |
| |
Liability |
(mil) |
19.7760 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
Achillion Pharmaceuticals, Inc. reported a net loss of $7,653,000 on revenues of $1,195,000 for the three months ended June 30, 2007, compared to a net loss of $5,078,000 on revenues of $2,167,000 during the samer period a year ago. The Company also used cash for ooperating activities totalling $13,991,000 during the recent quarter, compared to $10,277,000 used for operations during the same period last year. As a result of its recurring losses, the Company has an accumulated deficit of $139,050,000 as of June 30, 2007.
|
| |
|
Intellectual Property:
The Company's elvucitabine patent portfolio currently consists of 7 issued U.S. patents, 9 associated issued non-U.S. patents, 25 associated pending non-U.S. patent applications, 1 pending U.S. provisional application and 1 pending PCT application. The Company either owns or holds exclusive worldwide sublicenses from Vion Pharmaceuticals of patents owned by Yale University or exclusive worldwide licenses from Emory University to these patents and patent applications. Its hepatitis C patent portfolio currently consists of 3 U.S. provisional patent applications, 9 pending U.S. non-provisional applications, 2 associated issued non-U.S. patents, 91 associated pending non-U.S. patent applications and 3 pending PCT applications. In connection with the November 2004 collaboration with Gilead Sciences, the Company granted a worldwide exclusive license to Gilead Sciences for past, present and future patents, patent applications and patent filings with claims directed to its first NS4A antagonists and chemically-related compounds, any additional compounds which inhibit HCV via a mechanism similar to that of NS4A antagonism and intellectual property relating to the mechanism of action. In addition, the Company has obtained non-exclusive licenses to HCV drug discovery patents and patent applications owned by Chiron, a Novartis business unit, Apath, L.L.C. and ReBlikon, GmbH. The Company's antibacterial patent portfolio currently consists of 6 pending U.S. patent applications, 2 pending U.S. provisional patent application, 14 associated pending non-U.S. applications and 5 pending international patent applications filed under the Patent Cooperation Treaty. The HIV capsid patent portfolio currently consists of 2 pending U.S. patent applications, 1 pending international patent application filed under the Patent Cooperation Treaty and 8 associated non-U.S. patent filings. The Company has obtained an exclusive worldwide license to these patent applications from the University of Maryland Baltimore County. [SEC Filing 10-K 03-29-07]
|
| |
|
Description:
The Company engages in the discovery, development, and commercialization of treatments for infectious diseases.
|
| |
|
Officers:
Michael D. Kishbauch (Pres. & CEO); Milind S. Deshpande, Ph.D. (SVP & Chief Scientific Officer); John C. Pottage, Jr., M.D. (SVP & Chief Medical Officer); Gautam Shah, Ph.D. (SVP & Chief Compliance Officer); Mary Kay Fenton (VP & CFO)
|
| |
|
Auditor:
PricewaterhouseCoopers LLP
|
| |
|
Securities:
Common Stock-Symbol ACHN; NasdaqGM;
15,600,309 common shares outstanding as of August 1, 2007.
|
| |
| |
| |
| return to main page |
|
|
